Heron Therapeutics Inc
HRTX1.750USD
+0.060+3.55%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
266.75MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Heron Therapeutics Inc Unternehmen
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
Unternehmensinformationen
BörsenkürzelHRTX
Name des UnternehmensHeron Therapeutics Inc
IPO-datumAug 26, 1987
CEOMr. Craig Alexander Collard
Anzahl der mitarbeiter122
WertpapierartOrdinary Share
GeschäftsjahresendeAug 26
Addresse100 Regency Forest Drive
StadtCARY
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl27518
Telefon18582514400
Websitehttps://www.herontx.com/
BörsenkürzelHRTX
IPO-datumAug 26, 1987
CEOMr. Craig Alexander Collard
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
420.81K
+3.39%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
152.52K
+2.61%
Dr. William P. (Bill) Forbes
Dr. William P. (Bill) Forbes
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
138.94K
+2.87%
Dr. Sharmila Dissanaike, M.D.
Dr. Sharmila Dissanaike, M.D.
Independent Director
Independent Director
68.45K
-3.44%
Mr. Christian Waage
Mr. Christian Waage
Independent Director
Independent Director
66.18K
+26.70%
Mr. Craig A. Johnson
Mr. Craig A. Johnson
Lead Independent Director
Lead Independent Director
65.82K
-5.73%
Mr. Adam Morgan
Mr. Adam Morgan
Chairman of the Board
Chairman of the Board
32.89K
+19.94%
Mr. Michael Kaseta
Mr. Michael Kaseta
Independent Director
Independent Director
2.37K
-95.76%
Mr. Mark Hensley
Mr. Mark Hensley
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
420.81K
+3.39%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
152.52K
+2.61%
Dr. William P. (Bill) Forbes
Dr. William P. (Bill) Forbes
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
138.94K
+2.87%
Dr. Sharmila Dissanaike, M.D.
Dr. Sharmila Dissanaike, M.D.
Independent Director
Independent Director
68.45K
-3.44%
Mr. Christian Waage
Mr. Christian Waage
Independent Director
Independent Director
66.18K
+26.70%
Mr. Craig A. Johnson
Mr. Craig A. Johnson
Lead Independent Director
Lead Independent Director
65.82K
-5.73%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
CINVANTI
25.74M
66.17%
ZYNRELEF
8.04M
20.67%
SUSTOL
2.86M
7.35%
APONVIE
2.26M
5.81%
Nach RegionUSD
Name
Umsatz
Anteil
United States
38.90M
100.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
CINVANTI
25.74M
66.17%
ZYNRELEF
8.04M
20.67%
SUSTOL
2.86M
7.35%
APONVIE
2.26M
5.81%
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Rubric Capital Management LP
17.51%
The Vanguard Group, Inc.
5.39%
Adage Capital Management, L.P.
5.15%
BlackRock Institutional Trust Company, N.A.
5.11%
Velan Capital Investment Management LP
4.58%
Other
62.26%
Aktionäre
Aktionäre
Anteil
Rubric Capital Management LP
17.51%
The Vanguard Group, Inc.
5.39%
Adage Capital Management, L.P.
5.15%
BlackRock Institutional Trust Company, N.A.
5.11%
Velan Capital Investment Management LP
4.58%
Other
62.26%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
35.76%
Investment Advisor
24.53%
Investment Advisor/Hedge Fund
16.56%
Research Firm
3.08%
Private Equity
1.45%
Pension Fund
1.17%
Individual Investor
0.70%
Bank and Trust
0.14%
Venture Capital
0.06%
Other
16.54%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
350
127.68M
83.69%
-21.02M
2025Q1
384
126.94M
83.22%
-22.20M
2024Q4
390
118.52M
78.10%
-45.51M
2024Q3
400
125.21M
82.85%
-42.71M
2024Q2
402
132.96M
88.55%
-36.75M
2024Q1
402
122.65M
81.87%
-45.18M
2023Q4
413
115.58M
77.36%
-37.11M
2023Q3
417
122.12M
87.17%
-25.94M
2023Q2
428
102.54M
85.75%
-39.37M
2023Q1
447
111.46M
93.56%
-41.46M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Rubric Capital Management LP
26.71M
17.51%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
8.23M
5.39%
+67.98K
+0.83%
Mar 31, 2025
Adage Capital Management, L.P.
7.85M
5.15%
-648.00K
-7.62%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.79M
5.11%
-114.84K
-1.45%
Mar 31, 2025
Velan Capital Investment Management LP
6.99M
4.58%
--
--
Apr 21, 2025
Palisade Capital Management, LLC
5.29M
3.47%
+1.36M
+34.65%
Mar 31, 2025
Point72 Asset Management, L.P.
4.78M
3.13%
+1.70M
+55.27%
Mar 31, 2025
Tejara Capital Ltd.
4.58M
3%
-84.14K
-1.80%
Mar 31, 2025
State Street Global Advisors (US)
3.25M
2.13%
+107.71K
+3.42%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.11M
2.04%
+98.40K
+3.26%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.5%
iShares Micro-Cap ETF
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
Principal U.S. Small-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.5%
iShares Micro-Cap ETF
Anteil0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.02%
Principal U.S. Small-Cap ETF
Anteil0.02%
iShares Russell 2000 Value ETF
Anteil0.02%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.01%
Schwab U.S. Small-Cap ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
Global X Russell 2000 ETF
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
